You are currently viewing Novo Nordisk says experimental drug amycretin show 13% weight loss in trial 

Novo Nordisk says experimental drug amycretin show 13% weight loss in trial 

[ad_1]

Business & FinanceHealth

Reuters was first to report on the early trial data for Novo Nordisk’s highly anticipated experimental drug amycretin which showed that participants had a weight loss of 13.1% after 12 weeks, prompting the company’s shares to rise to record highs and placing it above Tesla by market valuation. 

Market Impact

Shares surged more than 8% to record highs, shooting Novo Nordisk up in global rankings to the 12th most valuable company from 14 previously.

Article Tags

Topics of Interest: Business & FinanceHealth

Type: Reuters Best

Sectors: Business & FinancePharmaceuticals & Healthcare

Regions: Americas

Countries: United States

Win Types: Speed

Story Types: Exclusive / Scoop

Media Types: Text

Customer Impact: Significant National Story

[ad_2]
Source link

Gadget Explorer Pro

Gadget Explorer Pro is an expert writer specializing in comprehensive reviews, insightful articles, and detailed comparisons of consumer electronics. With a passion for technology and years of experience, they offer unbiased analysis of the latest gadgets, from cameras to smart home devices. Known for making complex tech understandable, Gadget Explorer Pro helps readers make informed decisions. Follow them for expert advice and the latest trends in the world of technology.

Leave a Reply